Latest Regulatory Engagement News

Page 4 of 24
Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.
Ada Torres
Ada Torres
27 July 2026
CLINUVEL Pharmaceuticals is relocating its corporate headquarters to the United States and reducing its global workforce by up to 20%, realigning its operations to focus solely on the US pharmaceutical market and unlock greater capital access.
Ada Torres
Ada Torres
23 July 2026
Macquarie Group reports a 30% profit increase in FY26 to A$4.85 billion as CEO Shemara Wikramanayake announces retirement, with Greg Ward set to take the helm in November 2026.
Claire Turing
Claire Turing
23 July 2026
Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.
Ada Torres
Ada Torres
22 July 2026
Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.
Ada Torres
Ada Torres
22 July 2026
Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.
Ada Torres
Ada Torres
21 July 2026
CONNEQT Health's June quarter saw record consumer revenue growth and a 70% jump in enterprise subscription ARR, supported by a $5.5 million placement and progress on its FDA regulatory pathway for its cloud-based vascular analytics platform.
Ada Torres
Ada Torres
21 July 2026
Critical Minerals Group’s Pre-Feasibility Study for its Lindfield Vanadium Project delivers a robust $821 million pre-tax NPV and 26.6% IRR, setting the stage for a Definitive Feasibility Study and potential final investment decision in 2027.
Maxwell Dee
Maxwell Dee
20 July 2026
CGN Resources has bolstered its position in the Leonora gold district by acquiring the 142 km² Desdemona Project, expanding its landholding to 386 km². The company has initiated its first reverse circulation drilling program at Christmas Well targeting multiple high-priority gold prospects.
Maxwell Dee
Maxwell Dee
16 July 2026
Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.
Ada Torres
Ada Torres
14 July 2026
CLINUVEL Pharmaceuticals secures Canadian marketing approval for SCENESSE®, expanding access to the only approved systemic photoprotective treatment for erythropoietic protoporphyria (EPP).
Victor Sage
Victor Sage
13 July 2026
Imugene has secured $11.12 million through a placement to advance its allogeneic CAR-T therapy azer-cel after early clinical data showed complete responses in BTKi-resistant lymphoma patients.
Ada Torres
Ada Torres
7 July 2026

Browse the archive

Full archive